drugset
drugset / Trial / NCT02545439

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

NCT02545439 ↗

Phase 1 Completed 24 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.

Timeline

Start
2015-07
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown — Other
Background Rifampin Small molecule — —

Indications

No indication recorded.